In Vitro Assay for Listeria Immunotherapeutic Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the potency of Listeria-based immunotherapeutics in inducing antigen-specific CD8+ T cell responses are time-consuming, expensive, and not amenable to high-throughput analysis, relying on in vivo assays that require significant time and resources.
Innovation Solution
Development of in vitro cell-based assays that involve infecting antigen-presenting cells with Listeria-based immunotherapeutics expressing disease-associated antigenic peptides, co-culturing with T cells, and measuring cytokine production to assess antigen presentation and immune response induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If in vivo potency tests are used to assess Listeria-based immunotherapeutics, then reliable measurement of antigen-specific T cell responses is achieved, but the testing process becomes time-consuming (up to a month or more), expensive, and not amenable to high throughput
Solution Approach 1:
The patent creates an in vitro copy of the in vivo immune response assay. Instead of sacrificing animals and analyzing spleen T cells (original complex system), the invention uses cultured APCs and T cells in a controlled in vitro environment that replicates the key immunological interactions. This copying approach maintains measurement reliability while enabling high throughput screening of multiple immunotherapeutic candidates simultaneously
Solution Approach 2:
The invention extracts the essential immunological components (APCs, T cells, antigen presentation mechanism) from the complex in vivo system and isolates them for in vitro testing. By taking out only the necessary elements for measuring antigen-specific T cell responses and removing the animal model requirement, the assay achieves both reliability and high throughput capability
2Reliability
If in vivo potency tests are used to assess Listeria-based immunotherapeutics, then comprehensive immune response evaluation is achieved, but the testing cost increases significantly
Solution Approach 1:
The patent replaces expensive living animal subjects with disposable in vitro cell cultures. The immunotherapeutic potency is assessed using cultured APCs and T cells that can be discarded after a single assay, eliminating the need for expensive animal housing, care, and ethical compliance infrastructure while maintaining accurate immune response evaluation
Solution Approach 2:
By creating an in vitro model that copies the essential immunological interactions, the invention eliminates the need for expensive in vivo animal studies. The copied system uses affordable cell culture reagents and standard laboratory equipment, dramatically reducing testing costs while preserving the ability to accurately evaluate immune response induction
3Measurement precision
If in vivo potency tests are used to assess Listeria-based immunotherapeutics, then complete antigen-specific T cell response measurement is achieved, but the testing process is not readily amenable to high throughput analyses
Solution Approach 1:
The patent segments the complex in vivo assay into separate, manageable in vitro components: APC preparation, T cell preparation, co-culture conditions, and measurement protocols. This segmentation allows each component to be optimized independently and enables parallel processing of multiple samples, making the overall assay amenable to high throughput while maintaining measurement precision through standardized procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The in vitro assays provide a faster, less expensive, and more high-throughput capable method for evaluating the potency of Listeria-based immunotherapeutics, enabling efficient assessment of antigen-specific T cell responses and antigen presentation.
Implementation Method 1
These Lm-based immunotherapeutics utilize the phagosomal escape mechanism to introduce tumor antigens into antigen presenting cells (APCs)
Implementation Method 2
The antigen is then processed and loaded onto MHC I and MHC II molecules. Presentation of antigen epitopes on MHC II to CD4+T helper cells and in cross-presentation on MHC I to CD8+ cytotoxic T cells
Implementation Method 3
determining a cytokine production profile of the T cells, wherein an increase in cytokine production indicates expression of the antigen in infected APCs by the recombinant Listeria-based immunotherapeutic
Data Source
AI summary
Methods and compositions are provided for assessing antigen presentation and potency of Listeria-based immunotherapeutics in inducing an immune response.